NeoGenomics, Inc. (NEO) Downgraded by BidaskClub

NeoGenomics, Inc. (NASDAQ:NEO) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Wednesday, October 18th.

NEO has been the subject of a number of other research reports. ValuEngine upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Monday, August 7th. BTIG Research lowered shares of NeoGenomics from a “buy” rating to a “neutral” rating in a report on Monday, September 11th. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Friday, October 13th. Finally, Gabelli started coverage on shares of NeoGenomics in a research report on Thursday, August 24th. They set a “buy” rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $10.33.

Shares of NeoGenomics (NASDAQ NEO) traded down 0.47% during midday trading on Wednesday, hitting $8.49. The company had a trading volume of 476,426 shares. The company’s market capitalization is $674.00 million. The company’s 50-day moving average price is $10.25 and its 200 day moving average price is $9.02. NeoGenomics has a 12-month low of $7.12 and a 12-month high of $11.63.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.98%. The company had revenue of $63.05 million during the quarter, compared to analyst estimates of $63.11 million. During the same quarter last year, the business posted $0.04 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities research analysts predict that NeoGenomics will post $0.13 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “NeoGenomics, Inc. (NEO) Downgraded by BidaskClub” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/neogenomics-inc-neo-downgraded-by-bidaskclub-to-buy.html.

Several institutional investors have recently modified their holdings of NEO. American International Group Inc. grew its position in shares of NeoGenomics by 7.1% in the 1st quarter. American International Group Inc. now owns 32,643 shares of the medical research company’s stock worth $258,000 after buying an additional 2,152 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of NeoGenomics by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 22,164 shares of the medical research company’s stock worth $175,000 after buying an additional 545 shares during the last quarter. Teachers Advisors LLC grew its position in shares of NeoGenomics by 3.1% in the 1st quarter. Teachers Advisors LLC now owns 96,168 shares of the medical research company’s stock worth $759,000 after buying an additional 2,854 shares during the last quarter. Royce & Associates LP grew its position in shares of NeoGenomics by 0.5% in the 1st quarter. Royce & Associates LP now owns 607,000 shares of the medical research company’s stock worth $4,789,000 after buying an additional 3,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of NeoGenomics by 7.1% in the 1st quarter. Vanguard Group Inc. now owns 2,679,783 shares of the medical research company’s stock worth $21,144,000 after buying an additional 176,691 shares during the last quarter. 80.41% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply